Advances in the treatment of platinum resistant epithelial ovarian cancer: an update on standard and experimental therapies

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Malvezzi M, Carioli G, Rodriguez T, et al. Global trends and predictions in ovarian cancer mortality. Ann Oncol. 2016;27(11):2017–2025.
   PubMed Web of Science ®Google Scholar
• Matulonis UA. Management of newly diagnosed or recurrent ovarian cancer. Clin Adv Hematol Oncol. 2018;16:426–437.
   PubMed Web of Science ®Google Scholar
• Wilson MK, Pujade-Lauraine E, Aoki D, et al., Fifth ovarian cancer consensus conference of the gynecologic cancer intergroup: recurrent disease. Ann Oncol. 28(4): 727–732. 2017. .
   PubMed Web of Science ®Google Scholar
• Alvarez RD, Matulonis UA, Herzog TJ, et al. Moving beyond the platinum sensitive/resistant paradigm for patients with recurrent ovarian cancer. Gynecol Oncol. 2016;141(3):405–409.
   PubMed Web of Science ®Google Scholar
• Markman M, Markman J, Webster K, et al. Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design. J Clin Oncol. 2004;22(15):3120–3125.
   PubMed Web of Science ®Google Scholar
• Petru E, Angleitner-Boubenizek L, Reinthaller A, et al. Combined PEG liposomal doxorubicin and gemcitabine are active and have acceptable toxicity in patients with platinum-refractory and -resistant ovarian cancer after previous platinum-taxane therapy: a phase II Austrian AGO study. Gynecol Oncol. 2006;102(2):226–229.
   PubMed Web of Science ®Google Scholar
• Gordon AN, Fleagle JT, Guthrie D, et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol. 2001;19(14):3312–3322.
   PubMed Web of Science ®Google Scholar
• Mutch DG, Orlando M, Goss T, et al. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol. 2007;25(19):2811–2818.
   PubMed Web of Science ®Google Scholar
• Ferrandina G, Ludovisi M, Lorusso D, et al. Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J Clin Oncol. 2008;26(6):890–896.
   PubMed Web of Science ®Google Scholar
• Pujade-Lauraine E, Hilpert F, Weber B, et al., Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol. 32(13): 1302–1308. 2014. .
   PubMed Web of Science ®Google Scholar
• Stockler MR, Hilpert F, Friedlander M, et al. Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer. J Clin Oncol. 2014;32(13):1309–1316.
   PubMed Web of Science ®Google Scholar
• Friedlander M, Hancock KC, Rischin D, et al. A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer. Gynecol Oncol. 2010;119(1):32–37.
   PubMed Web of Science ®Google Scholar
• Pignata S, Lorusso D, Scambia G, et al. Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial. Lancet Oncol. 2015;16(5):561–568.
   PubMed Web of Science ®Google Scholar
• Lord CJ, Ashworth A. Targeted therapy for cancer using PARP inhibitors. Curr Opin Pharmacol. 2008;8(4):363–369.
   PubMed Web of Science ®Google Scholar
• Moore KN, Secord AA, Geller MA, et al., Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2019. 20(5): 636–648.
   PubMed Web of Science ®Google Scholar
• Frey MK, Pothuri B. Homologous recombination deficiency (HRD) testing in ovarian cancer clinical practice: a review of the literature. Gynecol Oncol Res Pract. 2017;4(1):4.
   PubMedGoogle Scholar
• Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764–775.
   PubMed Web of Science ®Google Scholar
• Telli ML, Timms KM, Reid J, et al. Homologous Recombination Deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer. Clin Cancer Res. 2016;22(15):3764–3773. .
   PubMed Web of Science ®Google Scholar
• Coleman RL, Sill MW, Bell-McGuinn K, et al. A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic oncology group study. Gynecol Oncol. 2015;137(3):386–391.
   PubMed Web of Science ®Google Scholar
• Boussios S, Abson C, Moschetta M, et al. Poly (ADP-Ribose) polymerase inhibitors: talazoparib in ovarian cancer and beyond. Drugs R D. 2020;20(2):55–73. .
   PubMed Web of Science ®Google Scholar
• De Bono J, Ramanathan RK, Mina L, et al. Phase I, dose-escalation, two-part trial of the parp inhibitor talazoparib in patients with advanced germline BRCA1/2 mutations and selected sporadic cancers. Cancer Discov. 2017;7(6):620–629. .
   PubMed Web of Science ®Google Scholar
• Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003;348(3):203–213.
   PubMed Web of Science ®Google Scholar
• Matulonis UA, Shapira-Frommer R, Santin AD, et al., Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study. Ann Oncol. 30(7): 1080–1087. 2019. .
   PubMed Web of Science ®Google Scholar
• Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer. Nature. 2013;500(7463):415–421.
   PubMed Web of Science ®Google Scholar
• Konstantinopoulos PA, Norquist B, Lacchetti C, et al., Germline and somatic tumor testing in epithelial ovarian cancer: ASCO guideline. J Clin Oncol. 38(11): 1222–1245. 2020. .
   PubMed Web of Science ®Google Scholar
• Hamanishi J, Mandai M, Ikeda T, et al. Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. J Clin Oncol. 2015;33(34):4015–4022. .
   PubMed Web of Science ®Google Scholar
• Omatsu K, Hamanishi J, Katsumata N, et al. 807O Nivolumab versus gemcitabine or pegylated liposomal doxorubicin for patients with platinum-resistant (advanced or recurrent) ovarian cancer: open-label, randomized trial in Japan (NINJA trial). Ann Oncol. 2020;31:S611.
   Web of Science ®Google Scholar
• Disis ML, Taylor MH, Kelly K, et al. Efficacy and safety of avelumab for patients with recurrent or refractory ovarian cancer: phase 1b results from the JAVELIN solid tumor trial. JAMA Oncol. 2019;5(3):393–401. .
   PubMed Web of Science ®Google Scholar
• Wakefield MJ, Nesic K, Kondrashova O, et al. Diverse mechanisms of PARP inhibitor resistance in ovarian cancer. Biochim Biophys Acta. 2019;1872(2):188307.
   Web of Science ®Google Scholar
• Noordermeer SM, Van Attikum H. PARP inhibitor resistance: a tug-of-war in BRCA-mutated cells. Trends Cell Biol. 2019;29(10):820–834.
   PubMed Web of Science ®Google Scholar
• Konstantinopoulos PA, Lheureux S, Moore KN. PARP inhibitors for ovarian cancer: current indications, future combinations, and novel assets in development to target DNA damage repair. American Society of Clinical Oncology Educational Book. 2020;(40):e116–e131. .
   Google Scholar
• Lin KK, Harrell MI, Oza AM, et al. BRCA reversion mutations in circulating tumor DNA predict primary and acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma. Cancer Discov. 2019;9(2):210–219.
   PubMed Web of Science ®Google Scholar
• Kondrashova O, Nguyen M, Shield-Artin K, et al. Secondary somatic mutations restoring RAD51C and RAD51D associated with acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma. Cancer Discov. 2017;7(9):984–998.
   PubMed Web of Science ®Google Scholar
• Dhillon KK, Swisher EM, Taniguchi T. Secondary mutations of BRCA1/2 and drug resistance. Cancer Sci. 2011;102(4):663–669.
   PubMed Web of Science ®Google Scholar
• Li H, Liu Z-Y, Wu N, et al. PARP inhibitor resistance: the underlying mechanisms and clinical implications. Mol Cancer. 2020;19(1):107.
   PubMed Web of Science ®Google Scholar
• Konstantinopoulos PA, Barry WT, Birrer M, et al. Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial. Lancet Oncol. 2019;20(4):570–580.
   PubMed Web of Science ®Google Scholar
• Liu JF, Barry WT, Birrer M, et al. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. Lancet Oncol. 2014;15(11):1207–1214.
   PubMed Web of Science ®Google Scholar
• Bell D, Berchuck A, Birrer M, et al. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474:609–615.
   PubMed Web of Science ®Google Scholar
• Andreassen PR, Ren K. Fanconi anemia proteins, DNA interstrand crosslink repair pathways, and cancer therapy. Curr Cancer Drug Targets. 2009;9(1):101–117.
   PubMed Web of Science ®Google Scholar
• Zou L. Ataxia telangiectasia–mutated and rad3-related inhibition and topoisomerase i trapping create a synthetic lethality in cancer cells. J clin oncol. 2018;36(16):1628–1630.
   PubMed Web of Science ®Google Scholar
• Kim H, Xu H, George E, et al. Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models. Nat Commun. 2020;11(1):3726.
   PubMed Web of Science ®Google Scholar
• Gogola E, Duarte AA, de Ruiter JR, et al. Selective loss of PARG restores parylation and counteracts PARP inhibitor-mediated synthetic lethality. Cancer Cell. 2018;33(6):1078–93.e12.
   PubMed Web of Science ®Google Scholar
• Coleman N, Zhang B, Byers LA, et al. The role of Schlafen 11 (SLFN11) as a predictive biomarker for targeting the DNA damage response. Br J Cancer. 2021;124(5):857–859.
   PubMed Web of Science ®Google Scholar
• Lin AB, McNeely SC, Beckmann RP. Achieving precision death with cell-cycle inhibitors that target DNA replication and repair. Clin Cancer Res off J Am Assoc Cancer Res. 2017;23(13):3232–3240.
   PubMed Web of Science ®Google Scholar
• Leijen S, van Geel RM, Sonke GS, et al. Phase II study of WEE1 inhibitor AZD1775 plus carboplatin in patients with TP53 mutated ovarian cancer refractory or resistant to first-line therapy within 3 months. J Clin Oncol. 2016;34(36):4354–4361.
   PubMed Web of Science ®Google Scholar
• Lheureux S, Cristea MC, Bruce JP, et al. Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2021;397:281–292.
   PubMed Web of Science ®Google Scholar
• Lee JM, Nair J, Zimmer A, et al. Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study. Lancet Oncol. 2018;19(2):207–215.
   PubMed Web of Science ®Google Scholar
• Konstantinopoulos PA, Cheng SC, Wahner Hendrickson AE, et al. Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2020;21(7):957–968.
   PubMed Web of Science ®Google Scholar
• Pujade-Lauraine E, Fujiwara K, Ledermann JA, et al. Avelumab alone or in combination with pegylated liposomal doxorubicin versus pegylated liposomal doxorubicin alone in platinum-resistant or refractory epithelial ovarian cancer: primary and biomarker analysis of the phase III JAVELIN ovarian 200 trial. Gynecol Oncol. 2019;154:21–22.
   Web of Science ®Google Scholar
• Ding L, Kim H-J, Wang Q, et al. PARP inhibition elicits STING-dependent antitumor immunity in brca1-deficient ovarian cancer. Cell Rep. 2018;25(2972–80.e5):2972–2980.e5. .
   Google Scholar
• Konstantinopoulos PA, Waggoner S, Vidal GA, et al. Single-arm phases 1 and 2 trial of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma. JAMA Oncol. 2019;5(8):1141–1149.
   PubMed Web of Science ®Google Scholar
• Färkkilä A, Gulhan DC, Casado J, et al. Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer. Nat Commun. 2020;11(1):1459.
   PubMed Web of Science ®Google Scholar
• Zamarin D, Burger RA, Sill MW, et al. Randomized phase ii trial of nivolumab versus nivolumab and ipilimumab for recurrent or persistent ovarian cancer: an NRG oncology study. J clin oncol. 2020;38(16):1814–1823.
   PubMed Web of Science ®Google Scholar
• Liu JF, Herold C, Gray KP, et al. Assessment of combined nivolumab and bevacizumab in relapsed ovarian cancer: a phase 2 clinical trial. JAMA Oncol. 2019;5(12):1731–1738. .
   PubMed Web of Science ®Google Scholar
• Zsiros E, Lynam S, Attwood KM, et al. Efficacy and safety of pembrolizumab in combination with bevacizumab and oral metronomic cyclophosphamide in the treatment of recurrent ovarian cancer: a phase 2 nonrandomized clinical trial. JAMA Oncol. 2021;7(1):78–85. .
   PubMed Web of Science ®Google Scholar
• Cadoo KA, Meyers ML, Burger RA, et al. A phase II randomized study of avelumab plus entinostat versus avelumab plus placebo in patients (pts) with advanced epithelial ovarian cancer (EOC). J clin oncol. 2019;37(15_suppl):5511. .
   Web of Science ®Google Scholar
• Lin LL, Lakomy DS, Ning MS, et al. Combining novel agents with radiotherapy for gynecologic malignancies: beyond the era of cisplatin. Int J Gynecologic Cancer. 2020;30(4):409–423.
   PubMed Web of Science ®Google Scholar
• Coats S, Williams M, Kebble B, et al. Antibody–Drug conjugates: future directions in clinical and translational strategies to improve the therapeutic index. Clin Cancer Res. 2019;25(18):5441–5448. .
   PubMed Web of Science ®Google Scholar
• Manzano A, Ocaña A. Antibody-Drug conjugates: a promising novel therapy for the treatment of ovarian cancer. Cancers (Basel). 2020;12(8):2223.
   Web of Science ®Google Scholar
• Lee EK, Liu JF. Antibody-drug conjugates in gynecologic malignancies. Gynecol Oncol. 2019;153(3):694–702. .
   PubMed Web of Science ®Google Scholar
• Moore K, Oza A, Colombo N, et al. 992O - FORWARD I (GOG 3011): a phase III study of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), versus chemotherapy in patients (pts) with platinum-resistant ovarian cancer (PROC). Ann Oncol. 2019;30:v403.
   Web of Science ®Google Scholar
• Levan K, Mehryar M, Mateoiu C, et al. Immunohistochemical evaluation of epithelial ovarian carcinomas identifies three different expression patterns of the MX35 antigen, NaPi2b. BMC Cancer. 2017;17(1):303.
   PubMedGoogle Scholar
• Hamilton EP, Barve MA, Tolcher AW, et al. 836P Safety and efficacy of XMT-1536 in ovarian cancer: a subgroup analysis from the phase I expansion study of XMT-1536, a NaPi2b antibody-drug conjugate. Ann Oncol. 2020;31:S627–S8.
   Web of Science ®Google Scholar
• Baeuerle PA, Reinhardt C. Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res. 2009;69(12):4941–4944.
   PubMed Web of Science ®Google Scholar
• Crawford A, Haber L, Kelly MP, et al. A mucin 16 bispecific T cell-engaging antibody for the treatment of ovarian cancer. Sci Transl Med. 2019;11(497):eaau7534. .
   Web of Science ®Google Scholar
• Jimeno A, Moore KN, Gordon M, et al. A first-in-human phase 1a study of the bispecific anti-DLL4/anti-VEGF antibody navicixizumab (OMP-305B83) in patients with previously treated solid tumors. Invest New Drugs. 2019;37(3):461–472.
   PubMed Web of Science ®Google Scholar
• Fu S, Burger RA, Hamilton E, et al. A phase Ib study of navicixizumab and weekly paclitaxel in heavily pretreated platinum resistant ovarian, primary peritoneal or fallopian tube cancer. Gynecol Oncol. 2020;159:14–15.
   Web of Science ®Google Scholar
• Kariolis MS, Miao YR, Diep A, et al. Inhibition of the GAS6/AXL pathway augments the efficacy of chemotherapies. J Clin Invest. 2017;127(1):183–198.
   PubMed Web of Science ®Google Scholar
• Rankin EB, Giaccia AJ. The receptor tyrosine kinase AXL in cancer progression. Cancers (Basel). 2016;8(11):103.
   PubMed Web of Science ®Google Scholar
• Bonifacio L, Dodds M, Prohaska D, et al. Target-Mediated drug disposition pharmacokinetic/pharmacodynamic model-informed dose selection for the first-in-human study of AVB-S6-500. Clin Transl Sci. 2020;13(1):204–211. .
   PubMed Web of Science ®Google Scholar
• Biopsace. Aravive announces successful completion of phase 1b trial evaluating AVB-500 in platinum resistant ovarian cancer. July 23, 2020. Available from: https://www.biospace.com/article/releases/aravive-announces-successful-completion-of-phase-1b-trial-evaluating-avb-500-in-platinum-resistant-ovarian-cancer/.
   Google Scholar
• Aravive. Aravive Announces GNW. Phase 3 trial design for AVB-500 in platinum resistant ovarian cancer pivotal trial expected to be initiated during 1Q21. November 19, 2020. Available from: https://ir.aravive.com/news-releases/news-release-details/aravive-announces-phase-3-trial-design-avb-500-platinum,
   Google Scholar
• Moore G, Annett S, McClements L, et al. Top no tch targeting strategies in cancer: a detailed overview of recent insights and current perspectives. Cells. 2020;9(6):1503.
   Web of Science ®Google Scholar
• Hu W, Liu T, Ivan C, et al. Notch3 pathway alterations in ovarian cancer. Cancer Res. 2014;74(12):3282–3293.
   PubMed Web of Science ®Google Scholar
• Ceccarelli S, Megiorni F, Bellavia D, et al. Notch3 targeting: a novel weapon against ovarian cancer stem cells. Stem Cells Int. 2019;2019:6264931.
   PubMed Web of Science ®Google Scholar
• McAuliffe SM, Morgan SL, Wyant GA, et al. Targeting notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy. Proc Nat Acad Sci. 2012;109(43):E2939–E48. .
   PubMed Web of Science ®Google Scholar
• Van Es JH, Van Gijn ME, Riccio O, et al. Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature. 2005;435(7044):959–963. .
   PubMed Web of Science ®Google Scholar
• Wu Y, Cain-Hom C, Choy L, et al. Therapeutic antibody targeting of individual Notch receptors. Nature. 2010;464(7291):1052–1057. .
   PubMed Web of Science ®Google Scholar
• Liu TC, Galanis E, Kirn D. Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nat Clin Pract Oncol. 2007;4(2):101–117.
   PubMedGoogle Scholar
• Msaouel P, Opyrchal M, Dispenzieri A, et al. Clinical Trials with Oncolytic Measles Virus: current Status and Future Prospects. Curr Cancer Drug Targets. 2018;18(2):177–187. .
   PubMed Web of Science ®Google Scholar
• Galanis E, Hartmann LC, Cliby WA, et al. Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Res. 2010;70(3):875–882.
   PubMed Web of Science ®Google Scholar
• Galanis E, Atherton PJ, Maurer MJ, et al. Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer. Cancer Res. 2015;75(1):22–30.
   PubMed Web of Science ®Google Scholar
• Friedlander M, Mercieca-Bebber RL, King MT. Patient-reported outcomes (PRO) in ovarian cancer clinical trials—lost opportunities and lessons learned. Ann Oncol. 2016;27:i66–i71.
   PubMedGoogle Scholar
• Markman M, Blessing J, Rubin SC, et al. Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a gynecologic oncology group study. Gynecol Oncol. 2006;101(3):436–440.
   PubMed Web of Science ®Google Scholar
• Miller DS, Blessing JA, Krasner CN, et al. Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the gynecologic oncology group. J Clin Oncol. 2009;27(16):2686–2691. .
   PubMed Web of Science ®Google Scholar
• Coleman RL, Brady WE, McMeekin DS, et al. A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a gynecologic oncology group study. Gynecol Oncol. 2011;122(1):111–115.
   PubMed Web of Science ®Google Scholar
• De Geest K, Blessing JA, Morris RT, et al. Phase II clinical trial of ixabepilone in patients with recurrent or persistent platinum- and taxane-resistant ovarian or primary peritoneal cancer: a gynecologic oncology group study. J Clin Oncol. 2010;28(1):149–153.
   PubMed Web of Science ®Google Scholar
• Safra T, Menczer J, Bernstein R, et al. Efficacy and toxicity of weekly topotecan in recurrent epithelial ovarian and primary peritoneal cancer. Gynecol Oncol. 2007;105(1):205–210.
   PubMed Web of Science ®Google Scholar
• Rose PG, Blessing JA, Mayer AR, et al. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a gynecologic oncology group study. J Clin Oncol. 1998;16(2):405–410.
   PubMed Web of Science ®Google Scholar
• Coleman RL, Oza AM, Lorusso D, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390(10106):1949–1961.
   PubMed Web of Science ®Google Scholar
• Lheureux S, Cabanero M, Cristea MC, et al. A randomized double-blind placebo-controlled phase II trial comparing gemcitabine monotherapy to gemcitabine in combination with adavosertib in women with recurrent, platinum resistant epithelial ovarian cancer: a trial of the princess margaret, California, Chicago and Mayo phase II Consortia. J clin oncol. 2019;37(27):5518. .
   Google Scholar